Development of a novel hybrid alphavirus-Nipah virus pseudovirion for rapid quantification of neutralization antibodies
Hetrick, B.; Nakka, S. S.; Yu, D.; Swineford, S.; Storm, N.; Griffiths, A.; Wu, Y.
Show abstract
Nipah virus (NiV) is an emergent paramyxovirus that causes serious disease in humans and animals. Accurate quantification of neutralizing antibodies (nAB) against NiV is essential for vaccine development. The current standard, the plaque reduction neutralization test (PRNT), requires authentic infectious NiV and BSL-4 containment, taking 4-7 days to complete. In this study, we developed a hybrid alphavirus-Nipah virus pseudovirion (Ha-NiV) composed of a non-replicating Nipah virus virus-like particle (VLP) that encapsulates an RNA genome from a fast-expressing SFV (Semliki Forest Virus) alphaviral vector. Ha-NiV can infect NiV target cells but is replication incompetent, enabling rapid quantification of nAB (6-18 hours) in BSL-2 conditions. We validated Ha-NiV using sera from Nipah virus-infected African green monkeys and established a good correlation (R2 = 0.86) with PRNT, demonstrating comparable specificity and sensitivity. These results demonstrate that the Ha-NiV assay can serve as a novel platform for convenient and rapid quantification of nAB in BSL-2 settings.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Indiscriminate activities of different Henipavirus polymerase complex proteins allow for efficient minigenome replication in hybrid systems 96%
- Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies 94%
- Application of the CPER reverse genetics system for genetic engineering of rabies virus 94%
Similar papers in this journal
- A novel rotavirus reverse genetics platform supports flexible insertion of exogenous genes and enables rapid development of a high-throughput neutralization assay 96%
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies 95%
- Propagation, inactivation, and safety testing of SARS-CoV-2 95%
Similar papers in this journal
- An efficient plasmid-based system for the recovery of recombinant vesicular stomatitis virus encoding foreign glycoproteins 96%
- Generation of OP7 chimera defective interfering particle preparations free of infectious influenza A virus that shows antiviral efficacy in mice 95%
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 95%
Similar papers in this journal
- Choosing the right tool for the job: A comprehensive assessment of serological assays for SARS-CoV-2 as surrogates for authentic virus neutralization 97%
- Detection of Mpox and other Orthopoxviruses using a Lateral Flow Device as a Point of Care diagnostic. 94%
- Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization 94%
Similar papers in this journal
- Development of an RT-RPA assay for La Crosse virus detection provides insights into age-dependent neuroinvasion in mice 95%
- Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions 95%
- An Optimized Circular Polymerase Extension Reaction-based Method for Functional Analysis of SARS-CoV-2 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.